linvoseltamab

Action and Spectrum

Action and spectrum: 

Linvoseltamab is an investigational bispecific antibody that connects CD3-expressing T cells to the B-cell maturation antigen on myeloma cells which enables T-cell activation and cancer cell death. 

In US every year 35 k individuals are affected with multiple myeloma. It is the second most cancer in the world which is distinguished by the growth of malignant plasma cells that harm organs. Most of these patients will experience disease progression and need further medications to improvise the manifestations. 

Drug Interaction

Adverse Reaction

Frequency not defined  

Cytokine release syndromes  

Immune effector cell–associated neurotoxicity syndrome (ICANS)  

Black Box Warning

Black box warning: 

The study is under investigation. 

Contraindication / Caution

Contraindication/Caution:   

The warnings include hypersensitivity, liver/kidney damage, and pregnancy. 

Pregnancy / Lactation

Pregnancy Warnings:  

Pregnancy category: Not assigned  

Lactation:  

Excretion of the drug into human breast milk is unknown  

Pregnancy Categories:  

Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.  

Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.  

Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.  

Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.  

Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.  

Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology: 

Multiple myeloma worsens after at least three prior treatments and is relapsed or resistant. linvoseltamab is under investigation to help this relapsed multiple myeloma. 

Pharmacodynamics: 

Linvoseltamab is a human bispecific T-cell engager (BiTE) antibody that binds to CD3 on cytotoxic T lymphocytes (CTLs) and BCMA-expressing tumor cells which activates and redirecting CTLs to kill BCMA-expressing tumor cells. A tumor necrosis receptor is BCMA which overexpresses plasma cells and promotes its survival. 

Adminstartion

Administration:  

Linvoseltamab is given IV route assuring its distribution and contact with targeted cells.  Clinical trial protocols or treatment regimens specify the precise dose and infusion schedule. 

Patient Information Leaflet

Patient information leaflet  

Generic Name: linvoseltamab  

Pronounced: LIN-vo-sel-TA-mab  

Why do we use linvoseltamab?  

linvoseltamab may be used to treat multiple myeloma which has not improved after at least three prior therapies.  The FDA’s clinical research effort for levometeletamab, which includes the Phase 1/2 pivotal study LINKER-MM1, is expected to make a decision. The trial’s results validates the BLA.